Final analysis of a phase 3 trial in 543 patients with unresectable hepatocellular carcinoma: first-line camrelizumab plus rivoceranib vs sorafenib gave median OS 23.8 vs 15.2 months (HR 0.64); treatment-related serious adverse events 25% vs 7%.
RCTn = 543
Qin et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study